# US 12,178,892 B2 · Compounds for positron emission tomography

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,892 B2
- Document ID: US12178892B2
- Status: Granted
- Kind: B2
- Application number: 17/488,810
- Filed: 2021-09-29
- Published: 2022-04-28
- Granted: 2024-12-31
- Earliest claimed: 2013-11-14
- Assignees: Purdue Research Foundation; Endocyte, Inc.
- Applicants: Endocyte, Inc.; Purdue Research Foundation
- Inventors: Iontcho R Vlahov; Christopher P Leamon; Philip S. Low; Garth L Parham; Qingshou Chen
- Web page: https://patentgrep.com/patent/US12178892B2

## CPC

- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61K 51/04: Organic compounds
- A61K 51/0459: {having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine}
- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.

## Claims

### Claim 1

A conjugate of formula
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A pharmaceutical composition comprising a conjugate according to claim 1 and a pharmaceutically acceptable excipient.